epiyangambin

a furofuran lignan; also a PAF receptor antagonist; from the leaves of Rollinia pickeli; RN given for epiyangambin, the (1S-(1alpha,3aalpha,4beta,6aalpha))-isomer; structure given in first source

Also Known As:

Networked: 11 relevant articles (5 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barbosa-Filho, José Maria: 2 articles (05/2014 - 04/2003)
2.	Tibiriçá, E: 2 articles (03/2001 - 01/2001)
3.	Almeida de Medeiros, Isac: 1 article (05/2014)
4.	Araújo, Islania Giselia Albuquerque: 1 article (05/2014)
5.	Bendhack, Lusiane Maria: 1 article (05/2014)
6.	Cavalcante, Karla Veruska Marques: 1 article (05/2014)
7.	Dias, Katy Lísias Gondim: 1 article (05/2014)
8.	Neto, Mario Dos Anjos: 1 article (05/2014)
9.	Silva, Darizy Flávia: 1 article (05/2014)
10.	Veras, Robson Cavalcante: 1 article (05/2014)

Related Diseases

1.	Anaphylaxis (Anaphylactic Shock) 11/01/1996 - "Protective effects of Yangambin - a naturally occurring platelet-activating factor (PAF) receptor antagonist - on anaphylactic shock in rats." 11/01/1996 - "The purpose of this study was to investigate the ability of yangambin to inhibit cardiovascular collapse and to reduce the mortality due to systemic anaphylaxis induced by antigen challenge in actively sensitized rats. " 11/01/1996 - "Moreover, yangambin and SR 27417, when administered 5 min before re-exposure of the animals to the antigen, markedly improved the survival rate at 120 min. These results confirm that PAF plays an important role in the pathophysiology of anaphylactic shock and show that yangambin presents good therapeutic potential in the treatment of the cardiovascular alterations observed during immediate hypersensitivity reactions." 06/01/1997 - "In addition, yangambin also suppressed the pleural neutrophil infiltration triggered by LTB4 as well as the blood thrombocytopenia and intestinal anaphylaxis elicited by antigen in rats. " 04/20/2003 - "Traditional medicinal uses of this plant are not known, but recent pharmacological studies with the isolated major constituent yangambin have shown various qualities: platelet activating factor (PAF) antagonist, protective effects against cardiovascular collapse and anaphylactic shock, anti-allergic properties, analgesic activity, and depressant effect in the central nervous system. "
2.	Shock 01/01/1996 - "It is concluded that yangambin is a selective antagonist of the cardiovascular effects of PAF and therefore constitutes a potential therapeutic agent in different shock states where abnormal PAF release is supposed to play an important role." 03/01/2001 - "The protective effects of a new, selective, plant-derived platelet-activating factor (PAF) antagonist, yangambin, on the cardiovascular alterations and mortality due to endotoxic shock were investigated in anaesthetized rats. " 03/01/2001 - "Finally, the acute (150 min) survival rates of endotoxic shock increased from 0% (LPS group) to 100% in the groups pretreated with either yangambin or WEB 2086. " 01/01/1996 - "Yangambin (3-30 mg kg(-1)) as well as the reference PAF antagonist WEB 2086 (0.1-1.0 mg kg(-1)) prevented the circulatory collapse elicited by the intravenous administration of PAF (0.5 μg kg(-1)), in a dose-dependent manner. " 03/01/2001 - "Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock."
3.	Thrombocytopenia (Thrombopenia) 06/01/1997 - "We also evidenced that the hemoconcentration, thrombocytopenia, and leucocytosis noted after i.v. PAF were all attenuated by yangambin. " 06/01/1997 - "In actively sensitized rats, pretreatment with yangambin failed to modify the antigen-induced hemoconcentration and leucocytosis, but dose-dependently abrogated the thrombocytopenia noted 1 h post-stimulation. " 05/01/1993 - "The ability of a furofuran lignan, epiyangambin, to inhibit PAF-induced rabbit platelet aggregation in vitro and thrombocytopenia in rats was investigated. " 09/01/1997 - "In guinea pigs, yangambin inhibited PAF-induced thrombocytopenia but did not affect leukocytopenia whereas SR 27417 afforded complete protection against both PAF-induced thrombocytopenia and leukocytopenia. " 06/01/1997 - "In addition, yangambin also suppressed the pleural neutrophil infiltration triggered by LTB4 as well as the blood thrombocytopenia and intestinal anaphylaxis elicited by antigen in rats. "
4.	Leukopenia 09/01/1997 - "In guinea pigs, yangambin inhibited PAF-induced thrombocytopenia but did not affect leukocytopenia whereas SR 27417 afforded complete protection against both PAF-induced thrombocytopenia and leukocytopenia. "
5.	Infections 01/01/2022 - "In this context, epi-yangambin proved more selective and effective against in vitro infection by L. "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Foropafant
3.	Antigens
4.	Anti-Allergic Agents (Antiallergic Agents)
5.	Analgesics (Analgesic Drugs)
6.	Catecholamines
7.	Endotoxins
8.	WEB 2086 (apafant)
9.	Lignans
10.	Leukotriene B4

Related Therapies and Procedures

1.	Intravenous Administration
2.	Controlled Hypotension